Proceeds will be used to increase the company's market penetration and develop further clinical data in support of the EnFix family of allograft products.
Data indicates that OXINIUM on highly cross-linked polyethylene has a 94.1% survivorship rate among all bearing combinations over a 20-year period for THA.